osis and Blood Transfusion Center, Taranto, Italy;4Thrombosis and Blood Transfusion, “Di Venere” Hospital, Bari, Italy; Thrombosis Center, Department of Clinical Pathology, Altamura,Italy; 6Thrombosis and Blood Transfusion Center, Molfetta, Italy;Department of Hematology, Acquaviva delle Fonti, Italy; 8Hemostasisand Thrombosis Center, Nocera Inferiore-Pagani-Scafati, Italy;Division of Internal Medicine, Gallipoli, Italy; 10Hemostasis Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, A. Department of Interdisciplinary Medicine, University of Bari, Bari,and Blood Transfusion Center, “San Paolo” Hospital, Bari, Italy;Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy;Italy Background: Oral anticoagulant therapy has been historically managed in Italy in sufferers with atrial fibrillation (AF) by a network of Anticoagulation Centers (ACs). Individuals taking direct oral anticoagulants (DOACs) no longer needed periodical blood withdrawal for the modification of the drug dosage and as a result their follow-up may be less strict than prior to. From 2018 onwards, 19 ACs of southern Italy happen to be utilizing a clinical model, named EGINA (Excellence model for the Integrated Management of New Anticoagulants), designed to enhance the management of such sufferers. Aims: To evaluate the incidence of ischemic and hemorrhagic events in patients taking DOACs, followed in line with the EGINA model. Solutions: This multi-center study included sufferers with AF who started a DOAC from Jan 2018 to Feb 2020. Information have been collected retrospectively by 9 ACs of southern Italy. The observational period lasted a maximum of 12 months from the date of initiation of therapy with a DOAC. Diagnosis of CA XII Inhibitor site significant and minor bleeding was made in accordance with the International Society on Thrombosis and Haemostasis (ISTH). Outcomes: All round 395 patients with AF has been assessed. Imply age was 75.76 years (SD = 9.48, ranging from 31 to one hundred years old) and 170 sufferers have been female (43 ). On average, at baseline assessment CHA2DS2-VASc score was 3.49 (SD = 1.three) and HAS-BLED 1.79 (SD = 0.95). The 33.two of sufferers were na e for anticoagulation. Apixaban was the most prescribed DOACs (35.four ), followed by edoxaban (32.four ), rivaroxaban (17.0 ) and dabigatran (15.2 ). DoseABSTRACT789 of|Aims: Examine the price of Stroke/SE (Ischemic, Hemorrhagic, Other) and Major Bleeding (ICH, GI, other web page) events and connected medical expenses among NVAF individuals prescribed oral anticoagulants (OACs). Approaches: Elderly patients with a NVAF diagnosis and OAC prescription (Caspase Activator manufacturer received January 1, 2013 – December 31, 2017) were identified inside the fee-for-service Medicare claims database. Patients were followed from OAC initiation to discontinuation, switch, disenrollment, death, or study end. Stroke/SE and MB associated hospitalizations and connected expenses have been identified using ICD-9 and ten principal diagFIGURE 1 Trough and peak level of dabigatran in patient who received 110mg compared with 150mg of dabigatran based on creatinine clearance nosis codes. Benefits: 738,283 patients with NVAF had been incorporated (apixaban: 34.0 , dabigatran: five.6 , rivaroxaban: 26.7 , warfarin: 33.six ). Patients average age was 78 years with imply CHA 2DS2-VASc score of four.five and HAS-BLED score of 3.4. Mean follow-up time was 300.5 days. 3.7 of sufferers had a MB (GI: 1.9 , ICH: 0.6 , Other: 1.five ). Among sufferers with MB, MB-related typical total medical fees were 19,505 plus the PPPM expense among all individuals was 171. GI bleed had the low